Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

Pieris Pharmaceuticals, Inc.. (3/9/18). "Press Release: Pieris Pharmaceuticals Reports Full-Year 2017 Financial Results and Corporate Update". Boston, MA.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 Seattle Genetics Inc. (Nasdaq: SGEN)
  Today Seagen Inc. (Nasdaq: SGEN)
  Group Seagen (Group)
Products Product Anticalin® scaffold technology
  Product 2 PRS-343 (CD137/HEr2 bispecfic anticalin-based drug, Pieris)
Index term Index term Seattle Genetics–Pieris: cancer immunotherapy, 201802– collab $30m upfront + $1.2b milestones + royalties developm antibody-anticalin fusion proteins
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Reine, Allan (Foghorn Therapeutics 201909– CFO before Pieris + Lombard Odier Asset Management + CIBC World Markets)

Record changed: 2021-06-10


Picture [iito] Plain Stupid Simple 650x80px

More documents for Pieris (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top